Advocacy intelligence hub — real-time data for patient organizations
Alkeus Pharmaceuticals, Inc. — PHASE3
Astellas Pharma Global Development, Inc.
Ray Therapeutics, Inc. — PHASE1, PHASE2
Heronova Pharmaceuticals — PHASE1
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts — NA
AAVantgarde Bio Srl — PHASE1, PHASE2
Splice Bio — PHASE1, PHASE2
Ascidian Therapeutics, Inc
Ascidian Therapeutics, Inc — PHASE1, PHASE2
AAVantgarde Bio Srl
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Susanne Kohl, PhD, LMHC, CASACT
Molecular Genetics Laboratory, Centre for Ophthalmology, University of Tuebingen
📍 ROCHESTER, NY
Fang Lu, MD
West China Hospital
Dr Samarendra Mohanty
Nanoscope Therapeutics Inc.
Murthy Chavali, MD, Ph.D.
Ocugen., Inc.
Brian P Brooks, M.D.
National Eye Institute (NEI)
📍 Bethesda, Maryland
Benedetto Falsini, MD
universita Cattolica del S. Cuore/Fondazione policlinico A. Gemelli, IRCCS
📍 Rome